Maravai LifeSciences Holdings Inc (NAS:MRVI)
$ 4.85 -1.28 (-20.88%) Market Cap: 687.94 Mil Enterprise Value: 938.85 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 71/100
Back to the Transcripts List

Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call Transcript

Nov 7, 2024 / 10:00 PM GMT
Release Date Price: $7.84 (-2.37%)

Key Points

Positve
  • Maravai LifeSciences Holdings Inc (MRVI) reported $65 million in revenue for Q3 2024, with $50 million coming from the Nucleic Acid Production (NAP) segment.
  • The company achieved a key milestone by completing its largest service build to date, producing 26 grams of mRNA material for a preclinical cell and gene therapy customer.
  • Maravai LifeSciences Holdings Inc (MRVI) has introduced 21 new products year-to-date, expanding its discovery mRNA synthesis services offerings.
  • The company has expanded its TriLink-owned IP around co-transcriptional capping technology, holding over 20 US and international patents.
  • Maravai LifeSciences Holdings Inc (MRVI) has signed a definitive agreement to acquire the DNA and RNA businesses of PCNA BiTE, enhancing its mRNA offering for early-phase discovery work.
Negative
  • Q3 2024 results were slightly below expectations due to customer-requested program timing shifts and muted demand in research and discovery products.
  • The company took a non-cash goodwill impairment charge of $154 million, impacting its financial performance.
  • Maravai LifeSciences Holdings Inc (MRVI) lowered its expected revenue range for 2024 to between $255 million and $265 million, a 5% reduction from previous guidance.
  • The Biologic Safety Testing (BST) segment continues to be pressured by a soft bioprocessing market backdrop.
  • The company anticipates adjusted EBITDA margin to decline to 16% to 18% due to lower revenue projections in higher-margin products.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MRVI.OQ - Maravai LifeSciences Holdings Inc
Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call
Nov 07, 2024 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified Participant [1]
--------------------------------------------------------------------------------
Yes, good afternoon, ladies and gentlemen, and welcome, everyone, to the my by Life Sciences Third Quarter 2020 for earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks and answer session, I would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one. Again. Thank you. I would now like to turn the call over to Debbie Hart. Please go ahead. Thank you. Good afternoon, everyone. Thanks for joining us on our third quarter 2024 earnings call. Our press release and the slides accompanying today's call are posted on our
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.